Disclosure of information is about providing information necessary for an informed decision of a patient and which is an essential element of knowingly valid consent. To obtain meaningful consent, information provided to a research topic should include the health status for which the research is proposed; The nature and purpose/cause of the study; The study of treatments or experimental procedures and methods; The likely risks and benefits of participating in research The nature of the disease and the possible outcomes if the condition is not treated; Availability, risks and benefits of alternative treatments The right to withdraw at any time; and all other information seems necessary for the patient to make an informed decision. [1–4] The above information should enable patients to make an informed, rational and logical decision in light of their cultural, psychological and social values and beliefs. While they invite subjects to participate in the research and have obtained their consent, potential subjects generally receive a document, an Informed Consent Information Document (ICD) consisting of a Patient Information Sheet (PIS) containing all the essential information relating to clinical trials in an easily understandable language that must be disclosed to the subjects, and a format, an IIC (ICCI) that must be signed by the applicant and/or the LAR to confirm his or her decision to be informed and the subject`s voluntary participation in the study. The research community recognized that the provision of a document containing all the necessary information alone may not fully guarantee that the individual has fully understood and understood the information necessary to make an informed decision. Therefore, the examiner must ensure that the subject has understood what participation means to him in order to make an informed decision. This is usually done through an interactive meeting with the subject who is interested in participation. This is where the Informed Consent Procedure (PKI) actually begins and where the CDI is primarily intended to identify and initiate PKI[1,17] [Figure 2]. The researcher reviews complete information on the subject and gives him sufficient time to read and understand research information, learn about each aspect of the research and voluntarily decide on participation in the research.
The investigator will then respond satisfactorily to any doubts and questions on the subject. After understanding the study information and reviewing the results of the study participation, the trial determines whether or not it participates in the study. If agreed, the applicant consents to participation in the study in writing by signing the ICF which confirms its decision to voluntarily inform and participate in the study. An impartial witness gives the consent of an illiterate, blind or physically disabled subject who may not be able to write by participating in the entire consent process if no trained ARA is formed.  The discerning witness, without conflict of interest, understands the information and transmits the likely subject by introducing a robust consent process and passing on the knowledge and responsibilities involved in the proposed research.